scPharmaceuticals Inc (SCPH) Shares Up Despite Recent Market Volatility

scPharmaceuticals Inc (NASDAQ: SCPH) has experienced a rise in its stock price by 9.00 compared to its previous closing price of 4.78. However, the company has seen a gain of 6.11% in its stock price over the last five trading days. Seeking Alpha reported 2024-03-13 that scPharmaceuticals Inc (SCPH) Q4 2023 Earnings Call Transcript

Is It Worth Investing in scPharmaceuticals Inc (NASDAQ: SCPH) Right Now?

Moreover, the 36-month beta value for SCPH is 0.05. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The public float for SCPH is 23.45M and currently, short sellers hold a 19.82% of that float. On April 04, 2024, SCPH’s average trading volume was 239.20K shares.

SCPH’s Market Performance

SCPH stock saw a decrease of 6.11% in the past week, with a monthly decline of -13.17% and a quarterly a decrease of -18.47%. The volatility ratio for the week is 6.23%, and the volatility levels for the last 30 days are 7.32% for scPharmaceuticals Inc (SCPH). The simple moving average for the past 20 days is -2.12% for SCPH’s stock, with a -21.23% simple moving average for the past 200 days.

Analysts’ Opinion of SCPH

Many brokerage firms have already submitted their reports for SCPH stocks, with Craig Hallum repeating the rating for SCPH by listing it as a “Buy.” The predicted price for SCPH in the upcoming period, according to Craig Hallum is $20 based on the research report published on September 07, 2023 of the previous year 2023.

Cowen, on the other hand, stated in their research note that they expect to see SCPH reach a price target of $25. The rating they have provided for SCPH stocks is “Outperform” according to the report published on December 01st, 2022.

Jefferies gave a rating of “Buy” to SCPH, setting the target price at $14 in the report published on October 21st of the previous year.

SCPH Trading at -4.28% from the 50-Day Moving Average

After a stumble in the market that brought SCPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.14% of loss for the given period.

Volatility was left at 7.32%, however, over the last 30 days, the volatility rate increased by 6.23%, as shares sank -11.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.62% lower at present.

During the last 5 trading sessions, SCPH rose by +6.11%, which changed the moving average for the period of 200-days by -51.58% in comparison to the 20-day moving average, which settled at $5.29. In addition, scPharmaceuticals Inc saw -16.91% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for SCPH

Current profitability levels for the company are sitting at:

  • -4.08 for the present operating margin
  • 0.72 for the gross margin

The net margin for scPharmaceuticals Inc stands at -4.15. The total capital return value is set at -0.68. Equity return is now at value -99.97, with -50.13 for asset returns.

Based on scPharmaceuticals Inc (SCPH), the company’s capital structure generated 0.51 points at debt to capital in total, while cash flow to debt ratio is standing at -1.52. The debt to equity ratio resting at 1.05. The interest coverage ratio of the stock is -13.84.

Currently, EBITDA for the company is -54.77 million with net debt to EBITDA at 0.13. When we switch over and look at the enterprise to sales, we see a ratio of 13.34. The receivables turnover for the company is 3.03for trailing twelve months and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.08.


To wrap up, the performance of scPharmaceuticals Inc (SCPH) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts